Dr. Brooks's group interest is in developing diagnostic and prognostic markers for urological diseases. They have approached this question broadly. They are active in biomarker discovery using genomic approaches. While their primary focus has been in prostate cancer, they have also worked in kidney bladder and testicular cancer. They are also actively seeking markers that reflect renal damage in patients with urinary obstruction. They are also interested in developing platforms for translating biomarkers discovered in the laboratory into clinical practice. For instance, they have active collaborations in developing novel molecular imaging strategies for prostate cancer. They also participate in several large clinical trials for development, validation and implementation of clinical biomarkers in prostate cancer.